Global Adrenomyeloneuropathy Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: July 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Adrenomyeloneuropathy Market was valued at $280 mn. in 2025. During the forecast period 2025-2030, it is expected to grow at 12.5% CAGR, to an estimated market size of $505 mn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
Adrenomyeloneuropathy (AMN) is the most common adult-onset phenotype of X-linked Adrenoleukodystrophy (X-ALD), a rare genetic disorder caused by mutations in the ABCD1 gene. It is characterized by the systemic accumulation of very long-chain fatty acids (VLCFAs), which leads to the progressive demyelination of the spinal cord and peripheral nerves, as well as adrenal insufficiency (Addison's disease).
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Adrenomyeloneuropathy Market in the period 2025-30:
- The expansion of newborn screening programs is significantly increasing the identifiable patient population before the onset of irreversible neurological symptoms.
- A major therapeutic shift is occurring from symptomatic management toward disease-modifying treatments, specifically targeting the underlying genetic cause via gene therapy.
- The market is benefiting from orphan drug designations and regulatory incentives that provide expedited approval pathways and market exclusivity for rare disease therapies.
- Integration of Artificial Intelligence and advanced data analytics is accelerating drug discovery and improving the accuracy of MRI-based diagnostics.
- High treatment costs for emerging one-time curative therapies, often exceeding USD 2 million, are creating significant reimbursement and accessibility challenges for healthcare systems.
- Increased patient advocacy and collaborative research initiatives between biotech firms and academic institutions are driving higher participation in clinical trials.
- The adoption of telehealth and remote monitoring platforms is improving long-term care management for adult patients with progressive mobility issues.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Gene Therapy
- Hormone Replacement Therapy
- Supportive & Symptomatic Care
- Stem Cell Transplant (HSCT)